Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.72 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | GLA | P06280 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | NPY1R | P25929 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | NPY2R | P49146 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20801120 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL3164693 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL8425718 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL40635 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL40634 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL23647923 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL17234118 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL14929512 | 1.00 | ADORA3 (0.72) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| SCHEMBL25100667 | 0.99 | ADORA3 (0.71) | ADORA3SLC29A1LMNAALDH1A1GLA | |
| Trimethylammonium SCHEMBL27839944 | 0.97 | ADORA3 (0.68) | ADORA3SLC29A1LMNAALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170044619-A1 | PROFILING CHEMICALLY MODIFIED DNA/RNA UNITS FOR DISEASE AND CANCER DIAGNOSIS | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK | 2017-02-16 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | ADORA3 103/4885SLC29A1 41/4885LMNA 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.